综上所述,KIT-D816、FLT3、WBC、2个疗程后流式细胞术MRD均为RUNX1-RUNX1T1融合基因阳性AML患者预后的影响因素。. This evidence concerns the gene RUNX1 and acute myeloid leukemia.